Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)18.52bn
- Net income in JPY-3.75bn
- Incorporated2006
- Employees621.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heartseed Inc | -100.00bn | -100.00bn | 45.49bn | 39.00 | -- | 6.32 | -- | -- | -- | -- | -- | 314.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.15 | -- | 0.00004 | -- | -- | -- | -- | -- | -- | -- |
| Healios KK | 104.00m | -2.22bn | 51.57bn | 65.00 | -- | 9.04 | -- | 495.87 | -25.70 | -25.70 | 0.9661 | 42.25 | 0.0067 | -- | 0.4952 | -- | -14.27 | -23.01 | -18.09 | -30.33 | -109.62 | -- | -2,143.27 | -2,221.73 | -- | -- | 0.5993 | -- | -81.43 | 30.96 | 47.65 | -- | -11.70 | -- |
| Shin Nippon Biomedical Laboratories Ltd | 31.37bn | 3.99bn | 69.90bn | 1.44k | 17.52 | 1.32 | 9.82 | 2.23 | 95.84 | 95.84 | 753.61 | 1,269.67 | 0.2983 | 1.01 | 5.59 | 21,848,400.00 | 3.73 | 9.90 | 5.31 | 14.82 | 51.59 | 52.68 | 12.50 | 23.35 | 0.6308 | -- | 0.4383 | 30.49 | 22.55 | 17.36 | -10.96 | 14.07 | 54.79 | 58.49 |
| 3-D Matrix Ltd | 8.47bn | 6.47m | 73.58bn | 114.00 | -- | 18.45 | 96.11 | 8.69 | -2.67 | -2.67 | 71.61 | 32.90 | 1.25 | 0.9849 | 4.61 | 74,276,300.00 | 0.0958 | -35.52 | 0.1222 | -46.12 | 68.67 | 59.66 | 0.0764 | -55.66 | 2.53 | -- | 0.2619 | -- | 51.11 | 59.47 | -878.94 | -- | -7.64 | -- |
| Takara Bio Inc | 44.15bn | -7.20bn | 114.52bn | 1.78k | -- | 1.13 | -- | 2.59 | -59.79 | -59.79 | 366.64 | 839.16 | 0.3535 | 1.48 | 5.49 | 24,816,750.00 | -5.73 | 8.66 | -6.12 | 9.70 | 53.99 | 63.76 | -16.20 | 17.16 | 3.83 | -4.82 | 0.0898 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| GNI Group Ltd | 26.84bn | -4.41bn | 143.66bn | 867.00 | -- | 2.86 | -- | 5.35 | -80.69 | -80.69 | 511.58 | 900.92 | 0.3447 | 2.18 | 4.01 | -- | -9.40 | 0.5414 | -11.37 | 0.6475 | 74.49 | 80.97 | -27.26 | 1.28 | 3.79 | -2.99 | 0.0941 | -- | 13.67 | 22.39 | -501.65 | -- | 34.24 | -- |
| SanBio Co Ltd | 0.00 | -3.44bn | 176.04bn | 29.00 | -- | 330.15 | -- | -- | -48.26 | -48.26 | 0.00 | 6.83 | 0.00 | -- | -- | 0.00 | -138.65 | -47.32 | -177.12 | -57.01 | -- | -- | -- | -- | -- | -12.42 | 0.725 | -- | -- | -- | -9.02 | -- | -46.04 | -- |
| Peptidream Inc | 18.52bn | -3.75bn | 203.92bn | 621.00 | -- | 3.93 | -- | 11.01 | -28.99 | -28.99 | 143.24 | 398.78 | 0.2182 | 3.75 | 3.32 | -- | -4.42 | 8.02 | -5.86 | 9.72 | 40.61 | 64.82 | -20.24 | 18.77 | 1.53 | -16.77 | 0.2485 | 0.00 | -60.32 | 9.66 | -124.97 | -- | 24.52 | -- |
Data as of Feb 17 2026. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
29.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 15 Apr 2025 | 11.05m | 8.50% |
| Taiyo Pacific Partners LPas of 30 Jan 2025 | 5.07m | 3.90% |
| Asset Management One Co., Ltd.as of 15 Sep 2025 | 4.57m | 3.52% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 3.47m | 2.67% |
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 3.30m | 2.54% |
| Baillie Gifford & Co.as of 31 Jan 2026 | 3.13m | 2.41% |
| Alma Capital Investment Management SA (UK)as of 30 Jun 2025 | 2.35m | 1.81% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 1.78m | 1.37% |
| Jupiter Asset Management Ltd.as of 31 Oct 2025 | 1.64m | 1.26% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.57m | 1.21% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
